Compare ARMP & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | WALD |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 187.3M |
| IPO Year | 1996 | 2021 |
| Metric | ARMP | WALD |
|---|---|---|
| Price | $5.41 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $15.00 | $2.00 |
| AVG Volume (30 Days) | 93.2K | ★ 159.2K |
| Earning Date | 05-07-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.89 |
| Revenue Next Year | N/A | $4.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $0.72 |
| 52 Week High | $14.98 | $3.22 |
| Indicator | ARMP | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 45.05 |
| Support Level | $5.12 | $1.24 |
| Resistance Level | $5.63 | $1.83 |
| Average True Range (ATR) | 0.47 | 0.07 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 84.37 | 45.24 |
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.